Phase IIb Data Suggest Benefit for Tulisokibart in Hidradenitis Suppurativa
A phase IIb trial presented at the EADV meeting in Vienna found encouraging results for tulisokibart, an experimental TL1A inhibitor, in hidradenitis suppurativa. In a MedPage Today video, Alexa Kimball discussed the drug's possible effect on scarring and fibrosis as well as early safety data. She described the week-16 efficacy findings as among the strongest seen in phase II studies of the condition.
At the EADV meeting in Vienna, phase IIb results for tulisokibart were presented in hidradenitis suppurativa. The drug is an investigational inhibitor of TL1A, a cytokine pathway related to TNF but acting differently. Alexa Kimball, MD, MPH, of Beth Israel Deaconess Medical Center, called the week-16 efficacy findings among the strongest seen in phase II studies of HS.
Kimball noted that TL1A influences both innate and adaptive immune cells and may also have antifibrotic effects. HS can create tunnel-like tracts beneath the skin and leave cordlike or plaque scars. Early safety data were reassuring and aligned with other TL1A programs, though longer follow-up is needed.
If later studies confirm the early phase IIb signal, tulisokibart could add a new mechanism to HS treatment and may be especially relevant for patients concerned about scarring and fibrosis. Clinicians and researchers may watch whether safety holds and whether antifibrotic effects translate into measurable benefit. Real-world impact would likely depend on long-term data, cost, and access, so the findings may shape expectations more than practice at this stage.